Table 2.

Echocardiographic assessment at healthy condition and after 28 days of right ventricular pacing

Characteristic	Healthy		Heart failure
	Tolvaptan group	Pecavaptan group	Tolvaptan group	Pecavaptan group
No. of animals	3	3	3	3
HR (bpm)	88 ± 8	103 ± 6	94 ± 11	89.6 ± 8.0
IVSd (cm)	0.8 ± 0.1	0.8 ± 0.1	0.8 ± 0.1	0.8 ± 0.1
LVPWd (cm)	0.6 ± 0.1	0.7 ± 0.1	0.7 ± 0.1	0.7 ± 0.1
LVIDd (cm)	2.8 ± 0.2	2.7 ± 0.1	3.3 ± 0.1*	3.3 ± 0.1*
LVIDs (cm)	1.8 ± 0.2	1.8 ± 0.1	2.8 ± 0.2**	2.7 ± 0.1***
EDV (mL)	29.3 ± 5.4	27.0 ± 2.9	45.6 ± 0.9*	44.8 ± 0.6*
ESV (mL)	10.7 ± 2.1	10.3 ± 0.5	30.1 ± 4.3*	28.3 ± 1.3**
EF (%)	64.0 ± 0.8	62.3 ± 1.7	34.0 ± 8.0*	37.4 ± 3.9*
FS (%)	33.3 ± 0.5	32.0 ± 1.6	15.8 ± 4.1*	17.4 ± 1.7*
SV (mL)	18.7 ± 3.4	15.7 ± 1.2	15.5 ± 3.4	16.9 ± 2.1

EDV, end‐diastolic volume; EF, ejection fraction; ESV, end‐systolic volume; FS, fractional shortening; HR, heart rate; IVSd, interventricular septum thickness at end diastole; LVPWd, left ventricular posterior wall thickness at end diastole; LVIDd, left ventricular internal dimensions at end diastole; LVIDs, left ventricular internal dimensions at end systole; SV, stroke volume.

Data are expressed as mean of n = 3 ± standard deviation. *P < 0.05, **P < 0.01, ***P < 0.001 compared to respective healthy group.